oral glp 1 microdose THE GLP-1 MICRODOSING PROGRAM Is GLP-1 microdosing for weight

10.1016/j.cmet.2007.10.008 146 ZiylanY

Eur J Heart Fail 22:196213 Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, Handelsman Y, Verma S, Anker SD, McMurray JJV, Kosiborod MN, Butler J (2020) Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization

Clinical Evidence: Reduced Cardiovascular Events Major cardiovascular outcome trials demonstrate significant benefits: LEADER trial: Semaglutide reduced major adverse cardiovascular events (MACE) by 13% compared to placebo in type 2 diabetes patients

It is also used to treat narcolepsy in children 12 and older and adults